Fortress Biotech Inc (FBIO)

$1.93 -0.04 (-2.03%)
Market Cap 58.25M
Revenue (ttm) 57.68M
Net Income (ttm) -46.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -79.75%
Debt to Equity Ratio 1.74
Volume 237,500
Avg Vol 216,912
Day's Range N/A - N/A
Shares Out 29.57M
Stochastic %K 49%
Beta 1.75
Analysts Strong Sell
Price Target $15.33

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 652 4500
Address:
1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States
ComeOnGuys
ComeOnGuys Jul. 18 at 2:49 PM
$FBIO it really wants to surpass 2$ resistance so badly.. let’s do it already and fly into double digit land 🤌🏽
0 · Reply
Deivittt
Deivittt Jul. 18 at 9:59 AM
$FBIO If you want to buy $DERM, it is interesting to do so through its parent company $FBIO since it is cheaper and they also give you the rest of the $FBIO drugs for free.
1 · Reply
MGeronimo
MGeronimo Jul. 18 at 3:33 AM
$FBIO IN AT 1.98 on product pipeline and increasing sales 5x normal buying
0 · Reply
FinSUN
FinSUN Jul. 17 at 6:47 PM
$FBIO makes sense 😂
1 · Reply
Zellchair
Zellchair Jul. 17 at 6:14 PM
$FBIO $FBIOP Perfect trading range. Those who want to reduce or increase their risk can do so without further volatility. I have sold more FBIOP today, and bought a little more $DERM.
0 · Reply
KeepYourDayJob
KeepYourDayJob Jul. 17 at 2:56 PM
$FBIO Shorts getting confident again to attack.
0 · Reply
dsoape
dsoape Jul. 17 at 2:11 PM
$FBIO someone mighta over reacted just a bit
0 · Reply
FinSUN
FinSUN Jul. 17 at 2:02 PM
$FBIO $16 😂
0 · Reply
FinSUN
FinSUN Jul. 17 at 1:56 PM
$FBIO https://www.tipranks.com/news/blurbs/fortress-biotech-fbio-receives-a-buy-from-roth-mkm-blurbs?utm_source=webullapp.com&utm_medium=referral
0 · Reply
OldManLogan
OldManLogan Jul. 17 at 1:04 PM
$FBIO $FBIOP Stock is so undervalued even based on DERM ownership alone, that about ZERO value was assigned to CAEL... this is also the advantage of the FBIO model with such a diversity of compounds being developed by partner companies...
1 · Reply
Latest News on FBIO
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Jul 14, 2025, 8:30 AM EDT - 4 days ago

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

DERM

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

Jun 24, 2025, 8:30 AM EDT - 24 days ago

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

DERM

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

Jun 20, 2025, 8:30 AM EDT - 4 weeks ago

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

DERM

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

Jun 9, 2025, 8:30 AM EDT - 5 weeks ago

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

DERM

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

May 30, 2025, 10:47 AM EDT - 7 weeks ago

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

FBIOP

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 15, 2025, 4:05 PM EDT - 2 months ago

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 14, 2025, 4:01 PM EDT - 2 months ago

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

May 13, 2025, 4:15 PM EDT - 2 months ago

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

CKPT

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

May 7, 2025, 4:01 PM EDT - 2 months ago

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

DERM

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 7, 2025, 8:00 AM EDT - 2 months ago

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

FBIOP

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

Apr 1, 2025, 4:01 PM EDT - 3 months ago

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

DERM

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Mar 31, 2025, 4:05 PM EDT - 3 months ago

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

Mar 28, 2025, 8:30 AM EDT - 4 months ago

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

CKPT

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 7:39 PM EDT - 4 months ago

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

FBIOP

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

Mar 26, 2025, 4:01 PM EDT - 4 months ago

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

DERM

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

Mar 24, 2025, 8:30 AM EDT - 4 months ago

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

DERM

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

Mar 19, 2025, 4:01 PM EDT - 4 months ago

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

DERM

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

Mar 17, 2025, 8:55 AM EDT - 4 months ago

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

FBIOP

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

Mar 12, 2025, 8:30 AM EDT - 4 months ago

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

DERM

Sun Pharma to Acquire Checkpoint Therapeutics

Mar 9, 2025, 10:06 PM EDT - 4 months ago

Sun Pharma to Acquire Checkpoint Therapeutics

CKPT

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

Mar 5, 2025, 4:15 PM EST - 4 months ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

MBIO

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

Mar 5, 2025, 4:01 PM EST - 4 months ago

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

DERM

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

Mar 4, 2025, 4:01 PM EST - 4 months ago

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

DERM

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Jan 27, 2025, 8:30 AM EST - 6 months ago

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

FBIOP

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Jan 23, 2025, 8:30 AM EST - 6 months ago

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

DERM

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

Jan 6, 2025, 8:00 AM EST - 6 months ago

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Jan 6, 2025, 8:00 AM EST - 6 months ago

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

FBIOP

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

Dec 13, 2024, 6:15 PM EST - 7 months ago

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

CKPT

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Nov 14, 2024, 4:10 PM EST - 8 months ago

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

FBIOP

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 12, 2024, 4:30 PM EST - 8 months ago

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

CKPT

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Nov 12, 2024, 4:01 PM EST - 8 months ago

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

DERM

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Nov 4, 2024, 7:00 AM EST - 9 months ago

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

DERM

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

Oct 25, 2024, 8:30 AM EDT - 9 months ago

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

DERM

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 3, 2024, 8:30 AM EDT - 10 months ago

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

DERM

Fortress Biotech to Participate in October 2024 Investor Conferences

Sep 26, 2024, 8:30 AM EDT - 10 months ago

Fortress Biotech to Participate in October 2024 Investor Conferences

FBIOP

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

Sep 20, 2024, 8:30 AM EDT - 10 months ago

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

FBIOP

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Sep 16, 2024, 7:30 AM EDT - 10 months ago

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

CKPT

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

Sep 9, 2024, 8:30 AM EDT - 11 months ago

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

DERM

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:30 AM EDT - 11 months ago

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FBIOP

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:15 AM EDT - 11 months ago

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

DERM

Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:00 AM EDT - 11 months ago

Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

CKPT

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

FBIOP

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

DERM

Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates

CKPT

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

DERM

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

Jul 25, 2024, 8:30 AM EDT - 1 year ago

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

FBIOP

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

Jul 25, 2024, 7:30 AM EDT - 1 year ago

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

CKPT

GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research

Jul 15, 2024, 8:00 AM EDT - 1 year ago

GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research

CKPT

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

Jul 11, 2024, 4:05 PM EDT - 1 year ago

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

DERM

ComeOnGuys
ComeOnGuys Jul. 18 at 2:49 PM
$FBIO it really wants to surpass 2$ resistance so badly.. let’s do it already and fly into double digit land 🤌🏽
0 · Reply
Deivittt
Deivittt Jul. 18 at 9:59 AM
$FBIO If you want to buy $DERM, it is interesting to do so through its parent company $FBIO since it is cheaper and they also give you the rest of the $FBIO drugs for free.
1 · Reply
MGeronimo
MGeronimo Jul. 18 at 3:33 AM
$FBIO IN AT 1.98 on product pipeline and increasing sales 5x normal buying
0 · Reply
FinSUN
FinSUN Jul. 17 at 6:47 PM
$FBIO makes sense 😂
1 · Reply
Zellchair
Zellchair Jul. 17 at 6:14 PM
$FBIO $FBIOP Perfect trading range. Those who want to reduce or increase their risk can do so without further volatility. I have sold more FBIOP today, and bought a little more $DERM.
0 · Reply
KeepYourDayJob
KeepYourDayJob Jul. 17 at 2:56 PM
$FBIO Shorts getting confident again to attack.
0 · Reply
dsoape
dsoape Jul. 17 at 2:11 PM
$FBIO someone mighta over reacted just a bit
0 · Reply
FinSUN
FinSUN Jul. 17 at 2:02 PM
$FBIO $16 😂
0 · Reply
FinSUN
FinSUN Jul. 17 at 1:56 PM
$FBIO https://www.tipranks.com/news/blurbs/fortress-biotech-fbio-receives-a-buy-from-roth-mkm-blurbs?utm_source=webullapp.com&utm_medium=referral
0 · Reply
OldManLogan
OldManLogan Jul. 17 at 1:04 PM
$FBIO $FBIOP Stock is so undervalued even based on DERM ownership alone, that about ZERO value was assigned to CAEL... this is also the advantage of the FBIO model with such a diversity of compounds being developed by partner companies...
1 · Reply
Zellchair
Zellchair Jul. 17 at 12:30 PM
$FBIO $FBIOP I find it strange that when there is undoubtedly negative news, most of the positive comments appear at the same time… Why not be transparent and call it what it is?
2 · Reply
Kconn52
Kconn52 Jul. 17 at 12:15 PM
$FBIOP mildly disappointing news but so much more positive going on with this company. As long as $FBIO is trading above $1 this is money good and the accumulated dividend clicks along at $.19 per share per month.
0 · Reply
FinSUN
FinSUN Jul. 17 at 11:52 AM
$FBIO of course, 2 major positive catalysts in recent months but it didnt move 1 mixed in a huge pipeline (with Astrazenca!) and it goes down... You can post all the BS you want and there is no denying of course the price movement sucks... bit time ..but you will never change my mind that there is an ongoing illegal manipulation on this stock. but hey, this is Wall Street, no surprise. Will buy as well below 1.8 and stay patient for whenever this company will flourish.. should it take 2 years. Good luck everyone 😘
0 · Reply
Pharm_Hand
Pharm_Hand Jul. 17 at 11:01 AM
$FBIO goin' nowhere, and it's raining....going nowhere. 2 steps forward, 2 steps backward. https://www.youtube.com/watch?v=jBDHj4UzLjk
0 · Reply
FinSUN
FinSUN Jul. 17 at 8:49 AM
$FBIO https://www.tipranks.com/news/company-announcements/astrazenecas-anselamimab-trial-shows-mixed-results
0 · Reply
FinSUN
FinSUN Jul. 17 at 8:48 AM
$FBIO I fail to see bad news... definitwly buysing more if it gets manipulated lower On July 16, 2025, AstraZeneca announced that its Phase III clinical trial for anselamimab, a treatment for AL amyloidosis originally developed by Caelum Biosciences, did not achieve statistical significance for its primary endpoint in certain patient stages. Despite this, the drug showed clinically meaningful improvements in a specific subgroup and was well tolerated, prompting AstraZeneca to continue evaluating the results and plan further discussions with global health authorities. The most recent analyst rating on stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Fortress Biotech stock, see the FBIO .
1 · Reply
Sawnchey
Sawnchey Jul. 17 at 6:15 AM
$FBIO It's a shame to see the CAEL-101 news. The 19m approval milestone would have been a nice bonus to look forward to in 26/27, however these figures are smaller in comparison to the commercial potential of DERM and a successful CUTX-101 approval. At market close, each Fortress share owned roughly 1.81 dollars of value in DERM, MBIO and ATXI, so if the stock dips below this price today, that's my buy signal. Overall I think that the future still looks very bright, this is just one of the features of having a broad development pipeline.
0 · Reply
MightyPumperDuck
MightyPumperDuck Jul. 17 at 3:05 AM
$FBIO I don't understand. Why is the Market Cap at $57 million? They own 40+% of DERM. The market Cap is less than DERM holding. Whaaaaaatt?! @ZeLLchair help me my Scandanavian brother.
1 · Reply
dsoape
dsoape Jul. 17 at 1:45 AM
$FBIO if it opens down, it’ll be a great buying opportunity. North of $2 real soon
0 · Reply
Billybuk1
Billybuk1 Jul. 17 at 1:37 AM
$FBIO 40000 shares after hour Down .17
0 · Reply
KeepYourDayJob
KeepYourDayJob Jul. 17 at 12:38 AM
$FBIO Is this crashing tomorrow?
1 · Reply
Zellchair
Zellchair Jul. 16 at 9:35 PM
$FBIO $FBIOP 8-K from CFO now. Same info as AstraZeneca/Alexion.
2 · Reply